When will the FDA reclassify BPC 157 to Category 1 Octagon AI FDA moves toward easing restrictions on certain peptides BioPharma Dive BPC 157 has a decades long safety record with zero deaths or hospitalizations. Yet, it's unapproved because the FDA process is too expensive and the business model doesn't allow for profit. Approved The U.S. Food and Drug Administration is moving toward allowing compounding pharmacies to produce more than a dozen injectable peptides that were banned because of potentially significant safety risks, the New York